News

Vitamin D reduced the signs of inflammation and nerve damage in a rat model of progressive multiple sclerosis (MS), a study shows. Low levels of the vitamin have been extensively linked with a higher risk of developing relapsing forms of the disease, but studies of vitamin D supplementation in…

The specialty pharmaceutical company Neuraxpharm will be responsible for marketing the multiple sclerosis (MS) therapy Briumvi (ublituximab) in regions outside the U.S., Canada, Mexico, and certain Asian countries as part of a new collaboration with TG Therapeutics worth $140 million in upfront payments alone. Neuraxpharm is…

Neurofilament light chain (NfL) protein levels can be used to assess neurodegeneration in children and adolescents with neurological disease, including multiple sclerosis (MS), even when they are not experiencing any symptoms, a study has found. The protein already had been established as a biomarker of disease activity and poor…

Following a ketogenic diet — one that’s low in carbohydrates and rich in fat — for six months significantly reduced measures of body fat and fatigue, eased disease symptoms, and improved exercise capacity, cognition, and arm and hand dexterity in people with relapsing-remitting multiple sclerosis (RRMS), a study showed.

A generic equivalent of oral Gilenya (fingolimod) significantly lowers relapse rates, slows disability progression, and works against new lesions developing in people with relapsing multiple sclerosis (MS), according to a real-world study in Turkey. Feedback from patients also was favorable, with most being satisfied with the generic treatment…

Treatment with Tecfidera (dimethyl fumarate) provides a similar long-term benefit for Black and Hispanic people with multiple sclerosis (MS) as is found in other racial and ethnic populations, according to five years of data from the real-world ESTEEM study. The study — which assessed the long-term safety and…

A web-based wellness intervention program that educated multiple sclerosis (MS) patients on dietary plans, stress management, sleep, and exercise recommendations significantly improved their fatigue and quality of life, according to data from a clinical study. The study, “Evaluation of a web-based program for the adoption of wellness behaviors…

NX210c, an investigational therapy for multiple sclerosis (MS) and other neurodegenerative diseases from Axoltis Pharma, will have its clinical development boosted as part of a collaboration with InSilicoTrials. The companies will use InSilicoTrials’ simulation platform to replicate the brain and spinal cord characteristics of people with neurological disorders…

In people with relapsing forms of multiple sclerosis (MS), relapses that occur in the first few years after the disease develops have a strong impact on rates of disability worsening — but after about 2.5 years, more relapses don’t consistently result in a greater worsening of disability, according to…

Pro-inflammatory immune cells that can target the brain may be activated in a specific region of the intestine by certain gut bacteria before migrating to the brain, according to a new study done in mice. Researchers say these findings provide a proof of concept for how some immune cells may…

Infants breastfed by mothers on Copaxone (glatiramer acetate) for relapsing forms of multiple sclerosis (MS) do not experience more adverse events, hospitalizations, or need more antibiotics for the first 1.5 years than those in the general infant population. That conclusion comes from new analyses of data from COBRA,…

Octave Bioscience has raised $30 million in financing to help accelerate commercialization efforts for its precision care program for people with multiple sclerosis (MS). “We have made significant progress in deploying our solution for multiple sclerosis patients,” William Hagstrom, founder and CEO of Octave, said in a…

For the first time, multiple sclerosis (MS) therapies have been added to the World Health Organization (WHO)’s Model Lists of Essential Medicines (EML), which names those regarded as meeting the most important needs of healthcare systems worldwide. Glatiramer acetate (sold as Copaxone with generics available), Mavenclad (cladribine)…

Dawn Health, a Danish digital health company, has developed a smartphone app to support and empower people living with multiple sclerosis (MS) as they navigate their chronic disease care. Launched this week in Germany, the free Ekiva-MS app is designed to help patients better track their symptoms…

A new artificial intelligence (AI) algorithm could help identify people at risk of developing multiple sclerosis (MS). “Our model’s performance suggests that AI-based prediction models could identify the risk for multiple sclerosis years before neurological symptoms appear,” Raj Gopalan, MD, a scientist at Siemens Healthineers, Tarrytown, New York, said…

The risk of developing multiple sclerosis (MS) was similar between first- and second-degree family members of people with relapsing-remitting MS (RRMS) and primary progressive MS (PPMS). The findings, which were consistent with previous studies suggesting that genetics and environment are relatively equal contributors to disease risk, also…

The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency, has recommended that PB006, a biosimilar version of Tysabri (natalizumab), be approved to treat adults with highly active relapsing-remitting multiple sclerosis (RRMS). The recommendation comes about a year after the regulatory agency…

In multiple sclerosis (MS), inflammation leads to less energy production in nerve fibers by reducing the levels of enzymes in a key molecular pathway, called the TCA cycle, that cells use to generate energy, a new study shows. These findings imply that boosting activity of the TCA cycle might…

Primary progressive multiple sclerosis (PPMS) can greatly reduce quality of life for patients and affect their ability to work, according to real-world data collected from a German MS registry. These results “confirm the steadily deteriorating course of PPMS accompanied by increasingly limited quality of life,” researchers wrote. The study,…

What a person eats in childhood can influence their future risk of developing multiple sclerosis (MS) and its clinical course, according to a recent Dutch study. A poor diet with more fast food, snacks, and candy as a child tended to be associated with a higher risk of developing…

Experiencing disability in the early stages of multiple sclerosis (MS), even without relapses, increases the risk of progression to secondary progressive MS (SPMS), a more severe form of the disease, a large study finds. Starting a disease-modifying therapy early on in the disease may decrease the SPMS…

Synaptogenix is teaming up with Cleveland Clinic for a Phase 1 clinical trial involving people with multiple sclerosis (MS) that will test the company’s lead candidate, bryostatin-1 — a therapy designed to prevent cognitive deficits in MS patients. “We are moving forward with our clinical development plans for…

People with multiple sclerosis (MS) who take their prescribed disease-modifying therapies (DMTs) as recommended have better long-term health outcomes and lower healthcare costs than those who don’t, a U.S. study finds. Adhering to treatment can help reduce relapses, slow disease progression, and reduce the economic burden on both…

A first-of-its-kind study is aiming to determine whether older adults with multiple sclerosis (MS) can safely stop taking disease-modifying therapies, also known as disease-modifying agents (DMAs). The project is being led by scientists at the new P-HOPER Center, officially the Population Health Outcomes and Pharmacoepidemiology Education and Research…

The presence of spinal cord lesions — alone or with brain lesions — on MRI scans was associated with a higher risk of clinical relapse for multiple sclerosis (MS) patients over those with just brain lesions, according to a recent study. Spinal and brain lesions together were also predictive…

With a planned merger in the works, Frequency Therapeutics is no longer advancing its remyelination therapies for multiple sclerosis (MS), and instead is exploring “strategic alternatives for the program,” the company has announced. The regenerative medicine company, which had aimed to develop a new approach to treating MS…

Relapsing-remitting multiple sclerosis (RRMS) patients with elevated levels of chloride in their cerebrospinal fluid (CSF), the fluid that bathes the central nervous system, may be at a higher risk of relapse, according to a study from China. Researchers propose that CSF chloride levels equal to or higher than 123.2…

Since their launch in the 2010s, the use of oral disease-modifying treatments (DMTs) for multiple sclerosis (MS) has increased substantially, while injectable DMTs have become less popular, according to a study based on U.S. commercial health insurance data. “While two injectable therapies known as platform injectables, were once the…

People with multiple sclerosis (MS) are at a greater risk than the general public of developing any type of dementia, with that of Alzheimer’s disease being more than twice as high and vascular dementia nearly four times as high, a study from Korea suggested. This risk also was higher…

People with multiple sclerosis (MS) living in the U.K. who identified as South Asian reported their first symptoms at a significantly younger age than self-reported white and Black individuals, according to preliminary data from the ADAMS project. ADAMS, which stands for the genetic Association study of individuals from…